載入中
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
前收盤價
US$17.88
+US$0.47 · +2.70%
盤中時間採用ET。市場資料可能有所延遲。
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
日內區間
目前US$17.88
52週區間
目前US$17.88
盤中時間採用ET。市場資料可能有所延遲。
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
日內區間
目前US$17.88
52週區間
目前US$17.88
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1535.5萬 USD | 1000.7萬 USD | 2554.6萬 USD | 138.1萬 USD | 302.9萬 USD |
| 銷貨成本 | 355.7萬 USD | 3.15億 USD | 3.26億 USD | 2.43億 USD | 1.69億 USD |
| 毛利 | 1179.8萬 USD | −3.05億 USD | −3.01億 USD | −2.42億 USD | −1.66億 USD |
| 研究與開發 | 2.61億 USD | 3.19億 USD | 3.3億 USD | 2.46億 USD | 2.96億 USD |
| 銷售、一般及管理費用 | 5671萬 USD | 8024萬 USD | 7858.1萬 USD | 6932.8萬 USD | 5974.8萬 USD |
| 營業費用 | 3.15億 USD | 6703.4萬 USD | 7215.9萬 USD | 5765.1萬 USD | 1.98億 USD |
| 利息收入 | 2703.5萬 USD | 3474.6萬 USD | 3104.5萬 USD | 878.6萬 USD | 83萬 USD |
| 折舊和攤銷 | 355.7萬 USD | 546.4萬 USD | 526.9萬 USD | 413萬 USD | 392.5萬 USD |
| 營業利益 | −3.03億 USD | −3.72億 USD | −3.73億 USD | −2.99億 USD | −3.65億 USD |
| 淨利 | −2.76億 USD | −3.38億 USD | −3.42億 USD | −2.91億 USD | −3.64億 USD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.25億0.01%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI8580.4萬0.87%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM8355.01萬0.11%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF3620.53萬0.04%954億 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB2311.14萬0.22%108.2億 USD0.44%US$206.49+3.00%
iShares Russell 2000 Growth ETFIWO2304.82萬0.17%139.17億 USD0.24%US$356.78+0.94%
Dimensional - US Small Cap ETFDFAS2193.74萬0.06%338.69億 USD0.31%US$78.35+0.32%
T. Rowe Capital Appreciation Equity ETFTCAF1755.31萬0.19%91.1億 USD0.31%US$43.59+0.90%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFAST. Rowe Capital Appreciation Equity ETFTCAFAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
